Douglas Jermasek, is an accomplished leader with over 20 years of biopharmaceutical industry experience. As Senior Vice President & General Manager of Genzyme/Sanofi's global renal business, he drove sales over a billion dollars, establishing Renvela® as the standard of care for the treatment of hyperphosphatemia for patients with chronic kidney disease (CKD) and achieving "blockbuster" status globally. Earlier in his career he held positions of progressive responsibility at Hybritech/Lilly, Abbott Labs, Agouron/Pfizer, Prometheus Labs, and Intercept. Mr. Jermasek received an MBA from the Marriott School of Management and a BS in biological science from Brigham Young University.
Hector F. DeLuca, is a co-founder of Deltanoid Pharmaceuticals, Inc. and is recognized as a world leader in vitamin D chemistry, biochemistry and medicine, and has nearly 820 filed and active patents on his technologies. The majority of commercially-developed vitamin D analogs have originated in Professor DeLuca’s university lab. Prior to establishing Deltanoid, Dr. DeLuca was involved in the development of eight drugs marketed worldwide with over $10 billion in worldwide sales, including Alfarol®, Zemplar®, Rocaltrol®, Hectorol® and several others. Dr. DeLuca has been a successful entrepreneur involved in the creation of the publicly held pharmaceutical firm Bone Care International (NASDAQ:BCII) that was later acquired by Genzyme/Sanofi. He also was a founder of Tetrionics, sold to SAFC. He also serves on the board of Kegonsa Capital Partners. Because of his expertise in the field of vitamin D, Dr. DeLuca has developed contacts with many major pharmaceutical companies world-wide, and has served as a consultant to many firms. Professor DeLuca was a faculty member in the Department of Biochemistry for over 50 years, and served for 30 years as Chairman of that department. He continues to maintain an active research program as an Emeritus Professor. He received his PhD in biochemistry from the University of Wisconsin-Madison, and honorary degrees of medicine from the University of Colorado, the Medical College of Wisconsin, the Karolinska Institute, Stockholm, and Queen’s University of Canada.
Margaret Clagett-Dame is a co-founder of Deltanoid Pharmaceuticals, Inc. and is known for her considerable experience in both vitamin A and vitamin D, and has over 400 patents filed and active. Dr. Clagett-Dame also brings experience in the pharmaceutical industry with one of the top 10 pharmaceutical companies in the U.S. She joined the faculty at the University of Wisconsin-Madison in 1989, and currently holds a joint appointment at the rank of Professor in the Department of Biochemistry, College of Agricultural and Life Sciences; and in the Pharmaceutical Sciences Division in the School of Pharmacy. She obtained her MS in Nutrition from the Pennsylvania State University and a PhD in Biochemistry from the University of Wisconsin-Madison.
Lori Plum brings over 15 years of experience in vitamin A and vitamin D research, and has worked in the University laboratories of both Drs. Clagett-Dame and DeLuca. She has over 400 filed and active patents to her credit. Dr. Plum attended North Dakota State University-Fargo where she received her BS in Nutrition and received her PhD in Nutritional Sciences from the University of Wisconsin-Madison.
Linda Leikness brings over 20 years of management experience in entrepreneurial environments and biotechnology to Deltanoid. Prior to joining Deltanoid, Ms. Leikness worked as Chief Financial Officer and Treasurer for PanVera Corporation, sold to Life Technologies/Thermo Fisher Scientific (NASDAQ: TMO), and also worked as Chief Financial Officer for Pleasant Company/American Girl, which was acquired by Mattel (NYSE:MAT). Ms. Leikness received her BA in Accounting from the University of Wisconsin- Milwaukee and is a Certified Public Accountant and Global Certified Management Accountant.